Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin

Larimar Therapeutics, Inc.

50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.
25 mg cohort: median FXN increase in skin 2.81 pg/µg; one allergic AE resolved; 18 of 19 completed.
Cash $86.8M as of Dec 31, 2023; expected runway into Q1 2025.
OLE initiated Jan 2024 starting 25 mg daily; interim data expected Q4 2024.
FDA discussions ongoing for accelerated approval using FXN as surrogate; BLA submission targeted 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.